

6 Literatur

1. Adam G, Buske A, Häring A, Kekulé A: Patentschrift Nr. 10129927. Deutsches Patent- und Markenamt München, **2004**
2. Akendengue B, Ngou-Milama E, Laurens A, Hocquemiller R: Recent advances in the fight against leishmaniasis with natural products. *Parasite* (**1999**), 3-8
3. Alves TMA., Zani CL: New tetrahydroisoquinolines from Hyeronima oblonga (Euphorbiaceae). *Tetrahedron Lett* 40 (**1999**), 205-208
4. Amato Neto V: Etiological treatment for infection by Trypanosoma cruzi. *Mem Inst Oswaldo Cruz* 94 (**1999**), Suppl I: 337- 339
5. Barile FA, Arjun S, Hopkinson D: In vitro cytotoxicity testing: Biological and statistical significance. *Toxicol In Vitro* 7 (**1993**), 111-116
6. Blaxter ML, Miles MA, Kelly JM: Specific serodiagnosis of visceral leishmaniasis using a Leishmania donovani antigen identified by expression cloning. *Mol Biochem Parasitol* 30 (**1988**): 259-70
7. Braga MS, Lauria-Pires L, Arganaraz ER, Nascimento RJ, Teixeira ARL: Persistent infections in chronic Chagas' disease patients treated with anti-trypanosoma cruzi nitroderivatives. *Rev Inst Med Trop S Paulo* 42 (**2000**), 157-161
8. Breuer H, Medina E, Rangel M: The role of the alkaloid Melochinin in the central american cattle paralysis. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 316 (**1981**), R24
9. Bringmann G, Hamm A, Gunther C, Michel M, Brun R, Mudugo V: Ancistroealaines A and B, two new bioactive naphthylisoquinolines, and related naphthoic acids from Ancistrocladus ealaensis. *J Nat Prod* 63 (**2000**), 1465-70
10. Bringmann G, Rischer H, Wohlfahrt M, Schlauer J: Biosynthesis of Antidesmone in Cell Cultures of Antidesma membranaceum (Euphorbiaceae): An unprecedented class of glycine-derived Alkaloids. *J Am Chem Soc* 122 (**2000**), 9905-9910
11. Bringmann G, Schlauer J, Rischer H, Wohlfarth M, Mühlbacher J, Buske A, Porzel A, Schmidt J, Adam G: Revised Structure of Antidesmone, an unusual alkaloid from tropical antidesma plants (Euphorbiaceae). *Tetrahedron* 56 (**2000**), 3691-3695
12. Bringmann G, Wohlfarth M, Haller R, Baer S, Brun R: Anitdesmone, a novel antitrypanosomal alkaloid. *Pharm Pharmacol Lett* 11 (**2001**), 47-48
13. Brun R, Lang W, Löscher T: Afrikanische Trypanosomiasis (Schlafkrankheit). In: Lang W, Löscher T (Hrsg.): Tropenmedizin in Klinik und Praxis. 2. neubearb. Auflage. Thieme, Stuttgart, New York, **2000**. S. 50-66
14. Brun R, Rab S: In vitro drug sensitivity of Trypanosoma congolese isolates. *Parasitol Res* 77 (**1991**), 341-345

15. Brun R, Schöneberger M: Cultivation and in vitro cloning of procyclic culture forms of *Trypanosoma brucei* in a semi-defined medium. *Acta Tropica* 36 (1979), 289-292
16. Bryant C: *Biochemistry*. In: Cox FEG (Hrsg): *Modern Parasitology: A Textbook of Parasitology*. Blackwell Scientific Publications, Oxford, London, Edinburgh (usw.), 1993. S 117-136
17. Buckner FS, Verlinde CLMJ, La Flamme AC, Van Voehis WC: Effective technique for screening drugs for activity against *Trypanosoma cruzi* using parasites expressing β -galactosidase. *Antimicrob Agents Chemother*, 40 (1997), 2592-2597
18. Buske A: Phytochemische Untersuchung der Afrikanischen Euphorbiaceen *Antidesma membranaceum* und *Antidesma venosum*. Dissertation (Chemie), MLU Halle/ Saale. Rhombos Verlag Berlin 2000
19. Buske A: Über Inhaltsstoffe der Afrikanischen Euphorbiaceae *Antidesma membranaceum*. Diplomarbeit (Chemie), MLU Halle/Saale., 1996
20. Buske A, Busemann S, Mühlbacher J, Schmidt J, Porzel A, Bringmann G, Adam G: *Antidesmone*, a novel type isoquinoline alkaloid from *Antidesma membranaceum* (Euphorbiaceae). *Tetrahedron* 55 (1999), 1079-1086
21. Castro JA, Diaz de Toranza EG: Toxic effects of Nifurtimox and Benznidazole, two drugs used against american trypanosomiasis (Chagas' disease). *Biomed Environ Sci* 1 (1988), 19-33
22. De Castro SL, Pinto MCRF und Pinto AV: Screening of natural and synthetic drugs against *Trypanosoma cruzi*. I Establishing a structure/ activity relationship. *Microbios* 78 (1994), 83-90
23. Chhabra S C, Mahunnah R L, Mshiu E N: Plants used in traditional medicine in Eastern Tanzania. III: Angiosperms (Euphorbiaceae to Menispermaceae). *J Ethnopharmacol* 28 (1990), 255-283
24. Chowdhury SF, Villamor VB, Guerrero RH, Leal I, Brun R, Croft SL, Goodman JM, Maes L, Ruiz-Perez LM, Pacanowska DG, Gilbert ICH: Design, synthesis and evaluation of inhibitors of trypanosomal and leishmanial dihydrofolat reductase. *J Med Chem* 42 (1999), 4300-4312
25. Coura JA, de Castro SL: A critical review on Chagas disease chemotherapy. *Mem Inst Oswaldo Cruz* 97 (2002), 3-24
26. Cox FEG: *Parasitic Protozoa*. In: Cox FEG (Hrsg): *Modern Parasitology: A Textbook of Parasitology*. Blackwell Scientific Publications, Oxford, London, Edinburgh (usw.), 1993. S 1-8
27. Croft SL, Brun R: In vivo and in vitro models for the identification and evaluation of drugs active against *Trypanosoma* and *Leishmania*. Vortrag anlässlich „COST B9 congress on antiparasitic chemotherapy“, Mai 1999, Montpellier
28. Croft SL, Urbina JA, Brun R: Chemotherapy of human leishmaniasis and trypanosomiasis. In: Hide G, Mottram JC, Coombs GH, Holmes PH (Hrsg.): *Trypanosomiasis and Leishmaniasis*. CAB International, 1997. S. 245-257

29. *Cunningham I*: New culture medium for maintenance of Tsetse tissues and growth of trypanosomatids. *J Protozool* 24 (1977), 325-329
30. *Denise H*, Barrett MP: Uptake and mode of action of drugs used against sleeping sickness. *Biochem Pharmacol* 61 (2001), 1-5
31. *Desjardins RE*, Canfield CJ, Haynes JD, Chulay JD: Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. *Antimicrob Agents Chemother*, 16 (1979), 710-718
32. *Desjeux P*: Global control and Leishmania HIV co-infection. *Clin Dermatol* 17 (1999), 317-325
33. *Diaz de Toranza EG*, Castro JA, Franke de Cazzullo DM, Cazzullo JJ: Interaction of Benznidazole with nuclear and kinetoplastic DNA, proteins and lipids from *Trypanosoma cruzi*. *Experientia* 44 (1998), 880-889
34. *Eckert J*: Protozoen. In: Kayser FH, Bienz KA, Eckert J, Zinkernagel RM: Medizinische Mikrobiologie (9. Aufl.), Thieme Verlag, Stuttgart, New York 1997. S.484-557
35. *El Rayah IE*, Kaminsky R, Schmid C, El Malik KH: Drug resistance in sudanese *Trypanosoma evansi*. *Vet Parasitol* 80(4) (1999), 281-287
36. *Falbe J*, Regnitz M (Hrsg.): Römpp Lexikon Chemie. Thieme Verlag, Stuttgart, New York 1998, S. 2851, 4262
37. *Filardi LS*, Brener Z: Susceptibility and natural resistance of *Trypanosoma cruzi* strains to drugs used clinically in Chagas disease. *Trans R Soc Trop Med Hyg* 81 (1987), 755-9
38. *Fournet A*, Rojas de Arias A, Ferreira ME, Nakayama H, Torres de Ortiz S, Schinini A, Samunido M, Vera de Bilbao N, Lavault M, Bonte F: Efficacy of the bisbenzylisoquinoline alkaloids in acute and chronic *Trypanosoma cruzi* murine model. *Int J Antimicrob Agents* 13 (2000), 189-95
39. *Freiburghaus F*, Kaminsky R, Nkunya MHH, Brun R: Evaluation of African medical plants for their in vitro trypanocidal activity. *J Ethnopharmacol* 55 (1996), 1-11
40. *Fröhlich SJ*, Mino de Kaspar H, Peran R, Vera de Bilbao N, Schinini A, Rojas de Arias A, Sanches Insfran N, Moreno Azorero R, Heidenkummer P; Klauf V: Beteiligung der Chagas-Krankheit (Amerikanische Trypanosomiasis) am inneren Auge. *Ophthalmologe* 94 (1997), 206-210
41. *Gutteridge WE* : Chemotherapy. In: Cox FEG (Hrsg): *Modern Parasitology: A Textbook of Parasitology*. Blackwell Scientific Publications, Oxford, London, Edinburgh (usw.), 1993. S 1-8
42. *Gottstein D*, Gross D, Lehmann H: Mikrotest mit *Cladosporidium cucumerinum* Ell. & Arth. zum Nachweis fungitoxischer Verbindungen auf Dünnschichtplatten. *Z ges Hyg* 30 (1984), 620-621
43. *Harder A*, Greif G, Haberkorn A: Chemotherapeutic approaches to protozoa: Kinetoplastida-current level of knowledge and outlook. *Parasitol Res* 87 (2001), 778-780

44. Harms-Zwingenberger G, Bienzle U: Leishmaniosen. In: Lang W, Löscher T (Hrsg.): Tropenmedizin in Klinik und Praxis. 2. neubearb. Auflage. Thieme, Stuttgart, New York, **2000**. S. 37-49
45. Harborne J B: Ökologische Biochemie. Spektrum Akademischer Verlag, Heidelberg, Berlin, Oxford, **1995**
46. Hoppe HA: Drogenkunde: Handbuch der pflanzlichen und tierischen Rohstoffe. 7. Auflage. Cram, de Gruyter & Co, Hamburg, **1958**, S. 83
47. Jones M M, Singh PK, Lane JE, Rodrigues RR, Nasset A, Suarez CC, Bogitsh BJ, Carter CE: Inhibition of Trypanosoma cruzi epimastigotes in vitro by iron chelating agents. *Arzneim Forsch* 46 (**1996**), 1158-1162
48. Kaminsky R, Brun R: In vivo and in vitro activities of trybazine hydrochloride against various pathogenic trypanosome species. *Antimicrob Agents Chemother* 42 (**1998**), 2858-2862
49. Kaminsky R, Schmid C, Brun R: An „in vitro selectivity index“ for evaluation of cytotoxicity of antitrypanosomal compounds. *In Vitro Toxicol* 9 (**1996**), 315-324
50. Kayser O, Kiderlen AF, Brun R: In vitro activity of aurones against Plasmodium falciparum strains K1 und NF54. *Planta Med* 67 (**2001**), 718-21
51. Khaw M, Panosian CB: Human antiprotozoal therapy: past, present and future. *Clin Microbiol Rev* 8 (**1995**), 427-43.
52. Kierszenbaum F: Chagas' disease and the autoimmunity hypothesis. *Clin Microbiol Rev* 12 (**1999**), 210-223
53. v. Kirchhoff L: Trypanosoma species (American trypanosomiasis, Chagas' disease): Biology of trypanosomes. In: Mandell, GL (Hrsg.): Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 4. Aufl. Churchill Livingstone, New York **1995**. S. 2442-2450
54. Knobloch J: Trypanosomiasis. In: Knobloch J (Hrsg.) Tropen und Reisemedizin. Gustav Fischer, Jena (usw.), **1996**. S. 257-271
- Lang W: Malaria. In: Lang W, Löscher T (Hrsg.): Tropenmedizin in Klinik und Praxis. 2. neubearb. Auflage. Thieme, Stuttgart, New York, **2000**. S.10-33.
55. Löscher T: Wichtige Medikamente in der Tropenmedizin. In: Lang W, Löscher T (Hrsg.): Tropenmedizin in Klinik und Praxis. 2. neubearb. Auflage. Thieme, Stuttgart, New York, **2000**. S. 664-690
56. Lucius R, Loos-Frank B: Parasitologie: Grundlagen für Biologen, Mediziner und Veterinärmediziner. Spektrum Akademischer Verlag, Heidelberg, Berlin, **1997**. S. 39-62
57. Luque F, Fernández-Ramos C, Entrala E, Rosales MJ, Navarro JA, Romero MA, Salas JM, Sánchez-Moreno M: In vitro evaluation of newly synthesized (1,2,4)triazolo(1,5a)pyrimidine derivatives against T. cruzi, Leishmania donovani and Phytomonas staheli. *Comp Biochem Physiol Part C* 126 (**2000**), 39-44

58. Martin MB, Grimley JS, Lewis JC, Heath HAT, Bailey BN, Kendrick H, Yardley V, Caldera A, Lira R, Urbina JA, Moreno SNJ, Docampo R, Croft SL, Oldfield E: Bisphosphonates inhibit the growth of *Trypanosoma brucei*, *Trypanosoma cruzi*, *Leishmania donovani*, *Toxoplasma gondii*, and *Plasmodium falciparum*: A potential route to chemotherapy. *J Med Chem* 44 (2001), 909-916
59. Masana M, de Toranza EG, Castro JA: Reductive metabolism and activation of benznidazole. *Biochem Pharmacol* 33 (1984), 1041-1045
60. Medina E, Spitteller G: Konstitutionsaufklärung des Melochinins, eines Pyridon-Alkaloids neuen Typus aus *Melochia pyramidata* L. (Sterculiaceae). *Chem Ber* 112 (1979), 376-81
61. Muegla-Serrano S, Le-Senne A, Fernández-Portillo C, Nogal JJ, Ochoa C, Gómez-Barrio A: In vitro and in vivo anti-*Trypanosoma cruzi* activity of a novel nitro-derivative. *Mem Inst Oswaldo Cruz* 97 (2002), 553-557
62. Muegla-Serrano S, Pérez-Serrano J, Gómez-Barrio A, Arán VJ, Rodríguez-Caabeiro F: Ultrastructural alterations induced by nifurtimox and another nitro derivative on epimastigotes of *Trypanosoma cruzi*. *Parasitol Res* 88 (2001), 97-101
63. Murta SM, Romanha AJ: In vivo selection of a population of *Trypanosoma cruzi* and clones resistant to benznidazole. *Parasitology* 116 (1998), 165-71
64. Murta SM, Ropert C, Alves RO, Gazzinelli RT, Romanha AJ: In vivo treatment with Benznidazole enhances phagocytosis, parasite destruction and cytokine release by macrophages during infection with a drug-susceptible but not with a derived drug-resistant *Trypanosoma cruzi* population. *Parasite Immunol* 21 (1999), 535-44
65. Nakajima-Shimada J, Hirota Y, Aoki T: Inhibition of *Trypanosoma cruzi* growth in mammalian cells by purine and pyrimidine analogs. *Antimicrob Agents Chemother* 40 (1996), 2455-2458
66. Navarra M, Cisneros-Fajardo E, Lehmann T, Sánchez-Delgado RA, Atencio R, Silva P, Lira R, Urbina JA: Towards a novel metal-based chemotherapy against tropical diseases: 6. Synthesis and characterization of new copper (II) and gold (I) clotrimazole and ketoconazole complexes and evaluation of their activity against *Trypanosoma cruzi*. *Inorg Chem* 40 (2001), 6879-6884
67. Neal JA, Croft SL: An in vitro system for determining the activity of compounds against the intracellular amastigote form of *Leishmania donovani*. *J Antimicrob Chemother* 14 (1984), 463-475
68. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, Burt AD, Fleming KA: Long-term safety and effectiveness of iron-chelating therapy with Deferiprone for thalassaemia major. *N Engl J Med* 339 (1998), 417-423
69. Oppenheimer FR, Michels PA: Enzymes of carbohydrate metabolism as potential drug targets. *Int J Parasitol* 31 (2001), 482-90
70. Pedrosa RC, De Bem AF, Locatelli C, Pedrosa RC, Geremias R, Wilhelm Filho D: Time-dependent oxidative stress caused by benznidazole. *Redox Rep* 6 (2001), 265-70

71. Perry LM: Medical plants from east and southeast asia: Attributed properties and uses. The MIT Press Cambridge, MA. **1980**, S. 137-138
72. Phillips RS: Current status of malaria and potential for control. *Clin Microbiol Rev* 14 (**2001**), 208-226
73. Piaggio E, Roggero E, Pitashny M, Wietzerbin J, Bottasso OA, Revelli SS: Treatment with benznidazole and its immunomodulating effects on *Trypanosoma cruzi*-infected rats. *Parasitol Res* 87 (**2001**), 539-555
74. Piaggio E, Sancéau J, Revelli S, Bottasso O, Wietzerbin J, Serra E: Trypanocidal drug Benznidazole impairs lipopolysaccharide induction of macrophage nitric oxide synthase gene transcription through inhibition of NF- κ B activation. *J Immunol* 167 (**2001**), 3422-3426
75. Rajaskariah, GHR: WorldLeish II: impressions from a 'new leishmaniac'. *Trends Parasitol* 17 (**2001**), 403-405
76. Revelli SL, Le Page C, Piaggio E, Wietzerbin J, Bottasso O: Benznidazole, a drug employed in the treatment of Chagas' disease, down-regulates the synthesis of nitrite and cytokines by murine stimulated macrophages. *Clin Exp Immunol* 118 (**1999**), 271-277
77. Roberts WL, Berman JD und Rainey PM: In vitro antileishmanial properties of tri- and pentavalent antimonial preparations. *Antimicrob Agents Chemother* 39 (**1995**), 1234-1239
78. Rätz B, Iten M, Grether-Bühler Y, Kaminsky R, Brun R: The Alamar Blue assay to determine drug sensitivity of African trypanosomes (*T. b. rhodesiense* and *T. b. gambiense*) in vitro. *Acta Tropica* 54 (**1997**), 139-147
79. Salmon-Chemin L, Buisine E, Yardley V, Kohler S, Debreu MA, Landry V, Sergheraert C, Croft SL, Krauth-Siegel RL, Davioud-Charvet E: 2- and 3-substituted 1,4-naphthoquinone derivatives as subversive substrates of trypanothione reductase and lipoamide dehydrogenase from *Trypanosoma cruzi*: synthesis and correlation between redox cycling activities and in vitro cytotoxicity. *J Med Chem* 44 (**2001**), 548-565
80. Sauerteig E, Weinke T: Amerikanische Trypanosomiasis. In: Lang W, Löscher T (Hrsg.): Tropenmedizin in Klinik und Praxis. 2. Neubearb. Auflage. Thieme, Stuttgart, New York, **2000**. S. 59-67
81. Sepúlveda-Boza S, Cassels BK: Plant metabolites active against *Trypanosoma cruzi*. *Planta Med* 62 (**1996**), 98-105
82. Schuster JP, Schaub GA: Experimental Chagas disease: the influence of sex and psychoneuroimmunological factors. *Parasitol Res* 16 (**2001**), 77-82
83. Singh PK, Jones MM, Lane JE, Nasset A, Zimmerman LJ, Ribeiro-Rodrigues R, Richter A, Stenger MR, Carter CE: Synthesis and in vitro trypanocidal activity of some novel iron chelating agents. *Arzheim Forsch* 47 (I) (**1997**), 311-315
84. Steglich W, Fugmann B, Lang-Fugmann S (Hrsg.): Römpp Lexikon Naturstoffchemie. Georg Thieme Verlag Stuttgart, **1997**, S. 428, 581

85. Tinto WF, Blyden G, Reynolds WF, McLean S: Constituents of *Hyeronima alchorneoides*. *J Nat Prod* 54 (1991), 1309-1313
86. Urbina JA: Chemotherapy of Chagas' disease: the how and why. *J Mol Med* 77 (1999), 332-338
87. Urbina JA, Lira JA, Visbal G, Batrolí J: In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite *Trypanosoma (Schizotrypanum) cruzi*. *Antimicrob Agents Chemother* 44 (2000), 2498-2502
88. Urbina JA, Payara G, Contreras LM, Liendo A, Sanoja C, Molina J, Piras M, Piras R, Perez N, Wincker P, Loebenberg D: Antiproliferative effects and mechanisms of action of SCH 56592 against *Trypanosoma (Schizotrypanum) cruzi*: In vitro and in vivo studies. *Antimicrob Ag Chemother* 42 (1998), 1771-1777
89. Villar JC, Marin-Neo JA, Ebrahim S, Yusuf S: Trypanocidal drugs for chronic asymptomatic *Trypanosoma cruzi* infection (Cochrane review). In: *The Cochrane Library* , 1, 2002. Oxford: Update Software
90. Webster GL: Synopsis of the Genera and Suprageneric Taxa of Euphorbiaceae. *Ann Missouri Bot Gard* 81 (1994), 33-144
91. Welburn SC, Fèvre EM, Coleman PG, Odiit M und Maudlin I: Sleeping sickness: a tale of two diseases. *Trends Parasitol* 17 (2001), 19-24
92. Werbowetz KA: Target-based drug discovery for Malaria, Leishmaniasis and Trypanosomiasis. *Curr Med Chem* 7 (2000), 835-860
93. WHO Fact Sheet No 116 (2000); <http://www.who.int/inf-fs/en/fact116.html>
94. WHO/ TDR: Chagas disease (2001); <http://www.who.int/ctd/chagas/disease.htm>
95. WHO/ TDR: New drug targets and leads for kinetoplastid drug discovery. TDR News 62 (2000); <http://www.who.int/tdr/publications/tdrnews62/kinetoplastid.htm>
96. Willcox ML, Cosentino MJ, Pink R, Bodeker G and Wayling S: Natural products for the treatment of tropical diseases. *Trends Parasitol* 17 (2001), 58-60